HYPERTENSION TREATMENT ALGORITHMS "MAY BE A DISSERVICE" TO PATIENTS
HYPERTENSION TREATMENT ALGORITHMS "MAY BE A DISSERVICE" TO PATIENTS who require individualized therapies, Jay Cohn, MD, University of Minnesota Medical School, declared at an American Society of Hypertension-funded press conference during the American Heart Association annual meeting in Dallas Nov. 16. Cohn said "treating hypertension is much more complex than a simple algorithm would suggest, because judgment is always required." Hans Brunner, MD, University of Lausanne, Switzerland, agreed: "It is essential that treatment is tailored to each patient; no general rule guarantees success."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth